Anti-hEGFR isotype family

The Anti-hEGFR isotype family features the variable region of cetuximab. Cetuximab is a chimeric human/mouse IgG1 monoclonal antibody that targets EGFR, a cell surface receptor overexpressed in many types of cancer. Binding of cetuximab to EGFR blocks ligand/receptor binding, and induces receptor internalization and subsequent degradation.
Cetuximab has been approved by the FDA for the treatment of metastatic colorectal cancer and metastatic squamous cell carcinoma of the head and neck.

Antibodies of the anti-hEGFR isotype family have been generated by recombinant DNA technology. They have been produced in CHO cells and purified by different types of affinity chromatography: protein G for IgG1 and IgG4 and peptide M for IgA2.

Anti-hEGFR-hIgG1Human EGFR (cetuximab) antibody - Human IgG1100 µg
Anti-hEGFR-hIgG1fut NEWHuman EGFR (cetuximab) antibody - Human IgG1, non-fucosylated100 µg
Anti-hEGFR-hIgG1NQ NEWHuman EGFR (cetuximab) antibody - Human IgG1, non-glycosylated100 µg
Anti-hEGFR-hIgG2 NEWHuman EGFR (cetuximab) antibody - Human IgG2100 µg
Anti-hEGFR-hIgG4 (S228P)Human EGFR (cetuximab) antibody - Human IgG4 (S228P)100 µg
Anti-hEGFR-hIgA2Human EGFR (cetuximab) antibody - Human IgA2100 µg
Disclaimer: Our products are provided for research purpose only. Commercial applications may require licensing from third parties.
Note that the sequence of available ORFs provided by InvivoGen can differ from a given reference Genbank record due to genetic variations and/or alternative splicing. Customers should verify that the version of a gene sold by InvivoGen is suitable for the customer needs.
Copyrights © 2011-2016 InvivoGen. All Rights Reserved. Reproduction of any materials from this site is strictly forbidden without permission for commercial use. Nonprofit use for non-commercial research and educational purposes is permitted, citation should include the URL "".